Categories: DevelopmentMarketMedtechSpecialty
A clinical stage specialty pharmaceutical company dedicated to the discovery and development of small-molecule antiviral therapeutics. Presidio’s main focus is on its HCV NS5A inhibitor program, currently undergoing clinical studies and is well positioned to compete in the growing HCV therapy market.
Investors 1
Mentions in press and media 2
| Date | Title | Description |
| 12.02.2008 | “Drug engineer” Numerate rises from the ashes of Pharmix | (UPDATED: See below.)
Numerate, a San Bruno, Calif., “drug engineer,” said it has acquired all intellectual-property assets of Pharmix, a Brisbane, Calif., startup that designed drugs via computer. The company’s release is here.
As you’d ex... |
| 29.08.2007 | Life sciences briefing: Wednesday, Aug. 29, 2007 | (UPDATED at 3:10pm PT: See below.)
Featured companies: Agendia, EndoGastric Solutions, FlowCo, Gentris, MedManage Systems, ParagonDx, Presidio Pharmaceuticals, Xoova
Presidio Pharma raises $26M for viral treatments — San Francisco’s Presidi... |
Reviews 0
